Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 5, 2016, by Cellectar Biosciences, Inc. The report discloses the entry into a material definitive agreement with INC Research, LLC, a contract research organization.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed relates to the estimated cost of a specific clinical study agreement.
- Estimated Study Cost: Approximately $3.7 million in aggregate fees for services, investigator grants, and pass-through costs.
Material Changes and Agreements
On December 5, 2016, the Company entered into a Work Order under a Master Services Agreement dated October 6, 2016, with INC Research. Key terms include:
- Scope: INC Research will provide services for an open-label, multi-center Phase II study of CLR 131 in patients with relapse or refractory select B-cell malignancies.
- Termination: Either party may terminate the Work Order for any reason upon 60 days' written notice.
- Cancellation Fee: In certain instances of early termination, the Company must pay a fee equal to 5% of the remaining project budget.
Outlook, Risks, and Contingencies
The filing does not contain updated financial guidance or general risk factors. The primary contingency noted is the potential for early termination of the study, which would trigger a cancellation fee obligation. The full text of the Work Order is intended to be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ending December 31, 2016.
Investor Verification Checklist
- Verify the status of the Phase II study for CLR 131 and patient enrollment progress.
- Review the full Work Order and Master Services Agreement when filed in the Form 10-K to understand specific cost breakdowns and termination clauses.
- Assess the Company's current cash position to determine if the $3.7 million estimated cost is covered by existing liquidity or requires additional financing.